ADAR1 Capital Management LLC Raises Position in VistaGen Therapeutics, Inc. $VTGN

Key Points

• ADAR1 Capital Management LLC significantly increased its stake in VistaGen Therapeutics, acquiring an additional 299,304 shares, resulting in a total ownership of 420,765 shares, valued at approximately $1,052,000.
• VistaGen Therapeutics reported earnings of ($0.47) per share for the last quarter, aligning with analysts' expectations, and generated revenue of $0.24 million during the same period.
• The current average analyst rating for VistaGen Therapeutics is a "Buy," with several firms adjusting their ratings in recent months, including an upgrade from "sell" to "hold."

ADAR1 Capital Management LLC lifted its position in shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) by 246.4% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 420,765 shares of the company's stock after acquiring an additional 299,304 shares during the quarter. ADAR1 Capital Management LLC owned approximately 1.46% of VistaGen Therapeutics worth $1,052,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Boothbay Fund Management LLC bought a new position in VistaGen Therapeutics during the fourth quarter worth about $66,000. Bank of America Corp DE boosted its holdings in VistaGen Therapeutics by 1,068.0% in the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company's stock worth $62,000 after buying an additional 19,331 shares during the period. Millennium Management LLC grew its stake in VistaGen Therapeutics by 52.9% in the 4th quarter. Millennium Management LLC now owns 38,732 shares of the company's stock valued at $114,000 after buying an additional 13,395 shares in the last quarter. Man Group plc purchased a new stake in shares of VistaGen Therapeutics during the fourth quarter worth $54,000. Finally, Stempoint Capital LP grew its holdings in VistaGen Therapeutics by 26.1% during the 4th quarter. Stempoint Capital LP now owns 2,328,492 shares of the company's stock valued at $6,869,000 after buying an additional 481,700 shares in the last quarter. 78.39% of the stock is owned by hedge funds and other institutional investors.

VistaGen Therapeutics Trading Down 1.9%

VistaGen Therapeutics stock traded down $0.07 during trading hours on Friday, hitting $3.55. 273,325 shares of the stock traded hands, compared to its average volume of 624,587. VistaGen Therapeutics, Inc. has a one year low of $1.90 and a one year high of $3.88. The company has a market cap of $108.91 million, a PE ratio of -1.99 and a beta of 0.55. The firm's 50-day moving average price is $2.84 and its two-hundred day moving average price is $2.55.

VistaGen Therapeutics (NASDAQ:VTGN - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.47). The company had revenue of $0.24 million during the quarter, compared to analyst estimates of $0.22 million. VistaGen Therapeutics had a negative net margin of 6,777.08% and a negative return on equity of 74.06%. On average, sell-side analysts expect that VistaGen Therapeutics, Inc. will post -1.77 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on VTGN. William Blair restated an "outperform" rating on shares of VistaGen Therapeutics in a research report on Wednesday, June 18th. Wall Street Zen upgraded VistaGen Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 16th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy".

About VistaGen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.